Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Daniel R. Budman
Trastuzumab-Dm1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer
The Open Breast Cancer Journal
Related publications
Effectiveness of Neoadjuvant Trastuzumab and Chemotherapy in HER2-overexpressing Breast Cancer
Journal of Cancer Research and Clinical Oncology
Medicine
Cancer Research
Oncology
T-Dm1, a Novel Antibody-Drug Conjugate, Is Highly Effective Against Uterine and Ovarian Carcinosarcomas Overexpressing HER2
Clinical and Experimental Metastasis
Medicine
Cancer Research
Oncology
T-Dm1 Reduces HER2+ Breast Cancer Recurrence
Cancer Discovery
Oncology
Prolonged Survival of Patients Receiving Trastuzumab Beyond Disease Progression for HER2 Overexpressing Metastatic Breast Cancer (MBC)
Oncology Research and Treatment
Cancer Research
Oncology
Hematology
Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine
Cancer Management and Research
Oncology
P3-013a Phase 1b Study of S-1 Combined With Trastuzumab Emtansine (T-Dm1) for HER2 Positive Metastatic Breast Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells With Primary Trastuzumab Resistance
Anti-Cancer Agents in Medicinal Chemistry
Cancer Research
Molecular Medicine
Pharmacology
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
Anti-Cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study
Pharmaceutical Research
Organic Chemistry
Biotechnology
Molecular Medicine
Pharmacology
Pharmaceutical Science
